Hemagglutinin (Influenza A virus H1N1 pdm09) (HA)

Hemagglutinin (HA) is the primary surface glycoprotein of the Influenza A virus H1N1 pdm09 strain, playing a fundamental role in the viral life cycle. It functions as a class I fusion protein that mediates viral entry by binding to alpha-2,6-linked sialic acid receptors on human upper respiratory tract cells (NCBI, 2023). Once the virus is internalized via endocytosis, the acidic environment of the endosome triggers a massive conformational change in the HA molecule, leading to the fusion of the viral and host membranes (UniProt, 2024). This process is essential for the release of the viral ribonucleoprotein complex into the host cell cytoplasm. Because HA is the most prominent surface antigen, it is the primary target for neutralizing antibodies induced by infection or vaccination (CDC, 2023). Therapeutic interventions include small molecules like umifenovir, which stabilizes the prefusion state of HA, and broadly neutralizing monoclonal antibodies that target the conserved stem region to prevent membrane fusion (PubMed, 2022). However, the rapid evolution of the HA head domain through antigenic drift remains a significant challenge for long-term vaccine efficacy and drug resistance (WHO, 2024). The pdm09-like designation specifically refers to strains derived from the 2009 H1N1 pandemic, which continue to circulate as seasonal influenza.

Other names

HAH1Hemagglutinin proteinSurface glycoproteinH1N1pdm09 HAInfluenza A H1N1 hemagglutinin (pdm09-like)

Inhibition of viral attachment to host cell sialic acid receptors or prevention of the pH-dependent conformational change required for fusion of the viral envelope with the endosomal membrane (PubMed, 2022).